RP
ANIP icon

Regal Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Regal Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,000
Closed -$1.01M – 36
2022
Q4 		$1.01M Buy
+25,000
New +$939K 0.24% 31

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Regal Partners's ANIP Position: Q1 2023 in Review

Regal Partners sold out of ANI Pharmaceuticals (ANIP) in Q1 2023, closing a stake of 25,000 shares — an estimated $1.01M sold.

Regal Partners first reported a position in ANIP in Q4 2022 and held it in 1 quarter. The position peaked at $1.01M in Q4 2022. 138 funds tracked by Wall St. Rank hold ANIP as of Q1 2023.

  • Regal Partners reported no remaining ANI Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Regal Partners sold 25,000 ANI Pharmaceuticals shares in Q1 2023, an estimated $1.01M.
  • Regal Partners first reported a position in ANI Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Regal Partners's ANI Pharmaceuticals position peaked at $1.01M in Q4 2022.
  • 138 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2023.

Based on Regal Partners's 13F filing for Q1 2023, filed 15 May 2023.